Canterbury DHB


HRT/OCP & Thrombosis

The use of the oral contraceptive pill and hormone replacement therapy, increases the risk of deep venous thrombosis in the general population.

This risk is significantly increased in thrombophillic women.

Thrombophilia testing prior to prescribing the OCP is only indicated where VTE has occurred in a first degree relative.

When thrombophilia or significant thrombotic risk is present, consider using either a:

If a woman is already on established OCP therapy without adverse events and is subsequently found to have the Factor V Leiden mutation, it is reasonable to maintain the OCP therapy.

HRT increases the risk of DVT/PE (relative risk about 2), and the influence of thrombophillia is additive for this group.

Transdermal HRT appears not to have significant thrombotic risk.

About this Canterbury DHB document (5197):

Document Owner:

Not assigned (see Who's Who)

Last Reviewed:

August 2016

Next Review:

August 2018


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5197